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1. Introduction 
Chronic Rhinosinusitis (CRS) constitutes a longstanding disease process and a significant 
health hazard. Its pathophysiology may entail inherent epithelial irregularities, infectious 
insults, antigenic fermentations, and anatomic abnormalities, acting separately or in 
cooperation. Hence, various state-of-the-art treatment modalities have evolved, focusing on 
the surgical restoration of sinus homeostasis: endoscopic approach and visualization, fine 
surgical tools, power-instrumentation, precise imaging, combination of intranasal and external 
accesses, and navigation techniques. Despite the impressive technological advances in 
operative interventions, the medical aspects of CRS have not been investigated to the same 
extent, and the relevant remedies have changed very little over the years. Topical therapy in 
CRS is a relatively novel methodology, which relies on the local pharmacological management 
of sinus inflammatory status, and aims to supplement the existing treatment options. Topically 
applied medications have been used successfully for decades in dermatology, ophthalmology 
and urology. This chapter reviews the philosophy of topical therapy for CRS, its applications 
and effectiveness, as well as our institution’s experience and findings regarding a complete 
local treatment protocol utilized for the management of refractory CRS. 
2. Refractoriness of CRS and the rationale for topical therapy 
CRS is one of the commonest chronic diseases, affecting 14.2% of the United States population 
(Lethbridge-Cejku et al., 2004). It places a substantial cost burden on the health care system 
and is responsible for a considerable portion of sick leaves and decreased productivity(Gliklich 
and Metson, 1998). The modern opinion points towards a multifactorial etiology which 
includes fungi, bacterial superantigens, allergy, aspirin sensitivity, exposure to environmental 
irritants, and lately, bacterial biofilms (Chiu et al., 2008).  Moreover, conditions impairing the 
mucociliary function, such as primary ciliary dyskinesia and cystic fibrosis(Armengot et al., 
1994) have also been implicated. The resulting chronic inflammation of the sinus mucosa leads 
to defense reactions and alterations, i.e. edema, high mucus secretion, cilia loss, and 
particularly, polyp formation (Meltzer et al., 2004).  
Surgery to remove the diseased mucosa and open the sinus ostia in order to restore the 
physiological mucociliary clearance, in combination with systemic antibiotics, has been the 
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mainstay of treatment for the past decades(Gosepath and Mann, 2005). The long-term 
success rate of endoscopic sinus surgery is reported as high as 76%. In the remaining 
patients, either no improvement is noted, or the CRS recurs soon after treatment. 
Interestingly, in the majority of failures, the post-operative sinus anatomy demonstrates 
ostium patency and wide-open ethmoid cavities, abundantly ventilated(Levine, 1990). 
Specifically, Kennedy has reported that 15% of patients who undergo endoscopic surgery, 
show mild to no clinical improvement, despite the “optimal” surgical outcome(Kennedy, 
1992). These difficult-to-treat patients sometimes demonstrate inflammatory or idiosyncratic 
features, such as eosinophilia, history of asthma, allergic fungal sinusitis, nasal polyps, and 
aspirin sensitivity(Zadeh et al., 2002). The common denominator of the above conditions, is 
an intrinsic pro-inflammatory state of the sinus mucosa which predisposes to 
clinicopathological exacerbations, in the absence of substantial external irritation. 
In addition to the aberrations of the end-organ, that is, the sinus epithelium, an unusual 
issue of resistance of ordinary bacteria to potent antimicrobials has emerged. This notable 
finding has been associated with the concept of biofilms, which cover the surface epithelium 
of paranasal cavities. The common bacterial species H. influenzae, S. pneumoniae, and S. 
aureus have been identified in biofilms, and their capacity to produce this organic matrix 
correlates with the refractoriness of CRS. Microorganisms colonizing the biofilms are much 
less vulnerable to systemic antibiotics which reach the standard tissue Minimally Inhibitory 
Concentration (MIC). Both the physical and chemical protection imposed by the organic 
layer on the microbial colonies, call for higher local concentrations of the antibacterial agents 
(Bendouah et al., 2006).  
The principle of the local therapy is prolonged delivery of a highly concentrated drastic 
substance, whether pharmacological or not, to the sinus cavities, so as to exert its maximal 
effect on the desired anatomical site, without significant systemic toxicity. Oftentimes, the 
existing antibiotics and anti-inflammatory medications produce a temporary relief from 
CRS, combined with mild to moderate side effects, depending on the comorbidities of the 
patient.  
3. Parameters affecting the efficacy of local treatment 
3.1 Macro-anatomy 
By definition, topical therapy should address thoroughly the target-organ, and reach all the 
subregions of the diseased paranasal cavities. Several patient- or drug-related factors 
influence the macro-delivery of medications, but the role of sinus surgery simply cannot be 
overstated enough.  
The paranasal sinuses, have limited communication with the nasal cavity proper, and this is 
even more evident in the disease state, when the edema and mucociliary impairment further 
restrict the access to the inflamed regions. This situation changes dramatically after a 
successful endoscopic surgery. Even if, because of the aforementioned idiosyncratic factors, 
the CRS persists, creation of wide, readily-accessible surgical cavities is critical for the 
efficient local application of the therapeutic agents (Fig. 1). The frontal and sphenoid sinuses 
practically cannot be reached by intranasal administration, while a minimal diameter  of 
4mm is required for a slightly accessible maxillary ostium(Harvey and Schlosser, 2009). 
During an endoscopic procedure, the maxillary entrance can be opened as widely as 2.5cm, 
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and the entire anterior wall of the sphenoid sinus may be removed. Regardless of the 
technique used for drug administration, the penetration in unoperated sinuses does not 
exceed 3% of the total volume placed intranasally(Hyo et al., 1989). On the other hand, 
radical surgical dissection allows contact of the drug with up to 96% of total sinus internal 
surface(Miller et al., 2004). Exactly how much improvement is provided by sinus surgery is 
difficult to assess though, as the various operative techniques are different in terms of 
intervention, and range broadly from minimally invasive (e.g. balloon sinuplasty) to 
extremely aggressive (e.g. modified endoscopic Lothrop procedure). Apart from the 
apparent gain in the total sinus surface contacted directly by the topical agents, clinical 
studies document as well that steroid sprays, when used by patients who had sinus surgery, 
produce more significant improvement of symptoms, endoscopical and histopathological 
findings, than in CRS sufferers having not being treated surgically(Lavigne et al., 2002). 
  
Fig. 1. In the unoperated patient (Left), the lateral nasal wall is an anatomical barrier to the 
delivery of topical medications, whereas the post-surgery paranasal cavities (Right) are 
accessible through wide windows. 
Individual anatomical details, further modify the pharmacological penetration into the 
paranasal cavities. Inferior turbinate hypertrophy limits the intranasal flow, whereas in case 
of uncorrected nasal septal deviation, accumulation of the local agent immediately anterior 
to the spur is noted. Moreover, the variations taking place during the nasal cycle influence 
the temporal pattern of drug dissemination. Altogether, a patent nasal passageway, not 
narrowed by all of the above anatomical factors, permits 90% penetration rate of the locally 
applied agents(Unno et al., 1983). 
A much debatable issue related to the delivery of local treatment is the patient’s optimal 
positioning during irrigations or nebulizations. The traditional “Mecca” position with the 
head brought forward is becoming now less popular than placing the head backward. 
Lateral positions have also been proposed as more appropriate for delivery to the frontal 
sinus(Karagama et al., 2001). 
A third consideration regarding the distribution of locally applied drugs is the configuration 
of sinuses in relation to gravity. Whereas the roof of the ethmoid and the frontal recess are 
dependent areas, so that the pharmacological deposits drain rapidly downwards, the 
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maxillary antrum with its highly-situated ostium retains most of its contents, until they are 
cleared by the mucociliary mechanism. 
3.2 Micro-anatomy 
Even when the local agent enters the sinuses in sufficient quantities, its efficacy is not 
guaranteed, as it needs to reach its pharmacological target, and stay in contact for an 
adequate amount of time. This becomes particularly important in the sinonasal cavities, 
where the microenvironment is structured specifically to eliminate foreign particles, 
including medications, using several clearance mechanisms. 
All sinus surfaces are covered by a mucus layer with the purpose to entrap foreign particles 
and filter the inhaled air. The production rate of the mucus fluctuates greatly, depending on 
the inflammatory status of the epithelium. Understandably, CRS is a condition predisposing 
to mucosal irritability and subsequent hypersecretion of thick mucus(Harvey and Schlosser, 
2009). The thickness of the viscous gel phase of the mucus layer, which overlaps the 
respiratory cell cilia, varies from 7 μm in healthy mucosa, to 200 μm in high-grade 
inflammatory states(Tarran et al., 2001). Mechanical removal of the viscous mucus blanket, 
by high-volume sinus rinses results in more potent effect of locally administrated 
steroids(Daviskas and Anderson, 2006). 
The mucus contents are as important as its physical dimensions and texture. Besides water, 
organic salts, enzymes, and immunoglobulins, the mucins constitute the basic ingredient of 
this supra-epithelial blanket. These are glycoproteins responsible for the viscous consistency 
of the mucus. In detail, mucins form fibers which bind to each other via cross-linking 
attachments, to make up a web that serves as the skeletal component of the three-
dimensional layer. The mucin tangle contributes to the support of air particles, but also 
presents a network of hydrophobic sites, that act as receptors for macromolecules with 
similar physicochemical properties. Hydrophobic molecules are retained in the mucus and 
exert a prolonged pharmacologic effect(Ugwoke et al., 2005). On the basis of this finding, 
conjugation of topical medications with mucoadhesive gels, aiming to achieve sustained 
drug release, has been proposed(Nakamura et al., 1999). 
In contrast with all the other Head and Neck sites, the sinonasal cavities are covered by 
respiratory-type epithelium, instead of the standard squamous-cell epithelial layer. Material 
that is captured in the mucus is gradually propelled outside the sinus cavities and carried to 
the nasopharynx, by means of constant ciliary beating. An intact mucociliary mechanism 
can clear the entire maxillary sinus of foreign particles in less than twenty minutes(Harvey 
and Schlosser, 2009). In CRS though, the chronic infection impairs the ciliary function, in 
favor of the prolonged residence of topically delivered medications. On the other hand, it is 
suggested that the active transfer of medications to the choanae might actually enhance their 
distribution to remote mucosal subsites(Goh and Goode, 2000). 
3.3 Major delivery techniques 
In the history of rhinosinusitis topical therapy, several methods for the delivery of the 
drastic agent have been utilized: Fluid irrigation, spray pumps, drops/powder/gel 
instillation, nebulization, and regional injection, aim to provide optimal spatiotemporal 
conditions of contact between the medication and its target. 
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Fluid irrigations remain a traditional, simple, and well-tested technique for conveying 
treatment formulas directly to the sinonasal surface epithelium. It is well-established that 
commercial nasal sprays, do not penetrate the frontal and sphenoid sinuses. On the 
contrary, a high volume of liquid solution (over 100mL) ensures access into these 
unapproachable sinuses. In post-operative cases, irrigations with a bulb syringe are superior 
to every other delivery methods, in terms of access to anatomical subsites. Yet, up to 30mL 
of solution pour out immediately from the nasal cavities, so that a considerable irrigation 
volume is wasted(Miller et al., 2004). Given a specific volume of solution, the pressure of 
irrigations can be modified by the device used. Low-pressure lavage using commercial pots, 
seem to be suitable for unoperated sinuses, whereas high-pressure douches delivered by 
squeeze-bottles are proper in case of surgically created open cavities(Harvey and Schlosser, 
2009).  
Nasal sprays have been classically used to provide local application of drugs in 
rhinosinusitis. Among the various devices developed over the years (spray bottles, aqueous 
pumps, dry powder atomizers), aqueous spray pumps are most accepted. Such pumps 
contain a medication-containing solution, which is released in the form of droplets. Smaller, 
lighter droplets demonstrate a broad distribution across the mucosal surface, as they travel a 
longer distance from the nostril. The viscosity of the solution is an additional factor, as 
thicker liquids project in a narrower cone and do not reach the peripheral intranasal 
regions(Kundoor and Dalby, 2010). Despite the refinements of spraying pumps, the droplets 
barely penetrate the sinuses in unoperated patients, and their effect is essentially restricted 
to the nasal cavities only. The maximal concentration of the sprayed agent is detected in the 
anterior nasal cavity, due to the obstructive mass of the inferior turbinate. Half of the dose 
does not approach the ostiomeatal complex, an anatomical structure central to the 
pathogenesis of CRS(Merkus et al., 2006).  
Nebulized medications are a novel topical approach to rhinosinusitis, and have been used 
for the past decade in clinical practice in Europe. In Japan, they were adopted in 1950, and in 
the United States, nebulizers and nebulized medications are covered by most medical 
insurances(Vaughan and Carvalho, 2002). Nebulization devices provide an aerosolized mist 
which is created by a mechanical pulse. The latter is produced either by a high-pressure jet, 
or a vibrating mesh. The earliest devices emitted an aerosolized stream of particles larger 
than 10μm, and the penetration of medications into the sinuses was limited as most of the 
particles are filtered by macro- or micro-anatomical barriers. Innovative technologies are 
now capable of generating airflow consisting of particles with a diameter less than 3μm, and 
accumulation on sinus mucosa is much more extensive. The main advantage of nebulizers, 
in comparison with the traditional spray pumps, is the deposition of pharmacological agents 
in the posterior nasal cavity. Moreover, sprayed formulations are undetected in the sinus 
cavities of patients who have not had surgery, whereas 8% of intranasally placed aerosols 
remain in the sinuses(Moller et al., 2010). 
4. Systemic absorption 
The advantage of topical therapy is the accumulation of very high concentrations of 
medications directly at the target site. Equivalent doses would not be possible to be 
administered systemically, due to unacceptable toxicity. Nonetheless, the systemic 
absorption of locally applied drugs should be always kept in mind, so that potential side-
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effects are avoided. The nasal mucosa incorporates a rich capillary network, and certain 
substances applied onto the broad epithelial cover of the sinus cavities may reach high 
concentrations in plasma. The significance of drug absorption by the nasal mucosa is 
evident from the strong interest in the design of intranasally administered systemic 
treatments for miscellaneous diseases, e.g. diabetes (insulin), migraine (propranolol, 
sumatriptan), smoking cessation (nicotine), osteoporosis (calcitonin), and acromegaly 
(octreotide)(Ranade, 2001). 
Orally administered medications undergo first-pass hepatic metabolism, and therefore a 
portion of the dose does not reach the systemic circulation. This is not the case in topical 
sinus medications, which are absorbed directly by the surface respiratory epithelium, and 
thus by-pass liver metabolism. However, the epithelial target cells of the nasal mucosa, 
contain an array of drastic enzymes, which also metabolize the pharmacological deposits. 
The levels of Cytochrome P-450, which participates in hepatic metabolism, are extremely 
high in the nasal mucosa, too. Phase II enzymes, like glutathione-transferase, which transfer 
micromolecular groups to the metabolized medications, are also prevalent. The nasal 
mucosa is deficient in proteases, though. Consequently, proteins are not lysed topically, and 
their absorption rate is substantial(Chien and Chang, 1987). 
5. Agents used in topical therapy 
5.1 Saline 
Prior to the local application of therapeutic antimicrobial or anti-inflammatory agents, 
mechanical cleansing of the sinuses with saline irrigations has been one of the oldest and 
most widely used methods for the management of CRS. Mucopurulent secretions filling up 
the infected cavities are a frequent finding in CRS exacerbations. Furthermore, during the 
post-operative period following endoscopic sinus surgery for chronic rhinosinusitis, a 
collection of old blood, crusts, necrotic debris, or allergic fungal mucin, is accumulating 
periodically and regular meticulous cleansing is as important as the surgical procedure 
itself(Palmer and Kennedy, 2003). Office debridement, with the help of curved suctions is 
the optimal way to maintain sinus health. However, it is impractical and uncomfortable for 
the patients to visit the rhinologist too often for debridements as the only means of 
removing the “toxic” material. Our own policy is performing this debridement on a weekly 
basis, until the sinus cavities are clean. Frequent, as needed saline irrigations may be 
performed easily at home and are the simplest and least expensive form of topical therapy. 
The appropriate saline concentration for the sinus lavage is controversial. Iso-, hypo-, and 
hyper-tonic salive, as well as Ringer’s Lactate solution, have all been tested for their efficacy 
and side effects. Isotonic saline is the basic irrigation solution, as it provides only mechanical 
cleansing, without creating an osmotic gradient between the sinonasal cavities and the 
surface epithelial cells. It is suggested though that the isotonic concentration also modifies 
the rheological properties of the mucus, making the secretions less viscous. On the other 
hand, hypertonic solutions have been introduced subsequently into CRS management, as 
they decrease mucosal edema by creating an efflux of water from the intercellular space. Not 
only that, but it is documented that hypertonic irrigations improve the mucociliary function, 
in comparison to isotonic saline. High salt concentration in the sinus cavities is postulated to 
promote intracellular calcium release, which sets off the biochemical cascade resulting to 
cilia movement(Daviskas et al., 1996). Hypertonic sinus lavage also has an effect on allergic 
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rhinitis, a major component of the CRS pathogenesis. Its main drawback however, is the 
discomfort often reported by the patients. 
Apart from their chemical composition and salt concentration, a second characteristic of 
saline douches, unique in topical therapy, is the high volume of solution used in each 
irrigation. The importance of volume and pressure parameters has already been described. 
Altogether, the benefit from saline irrigations to the management of CRS includes the 
mechanical removal of infectious/irritating/allergenic material, decrease of mucosal edema, 
improvement of the mucociliary function, and thinning of mucus secretions. Usually, saline 
rinses are prescribed in combination with other means of topical therapy, and there is 
evidence that they enhance the bio-supply of the primary medications(Papsin and 
McTavish, 2003). 
5.2 Corticosteroids 
Intranasal steroids have been initially the mainstay of topical therapy for allergic rhinitis. 
Due to their potent anti-inflammatory action, especially the deceleration of late-phase 
response, they diminish the manifestations of nasal allergy (congestion, rhinorrhea, 
pruritus). Their anti-decongestant properties in allergic rhinitis had been appreciated, and 
local steroids were subsequently introduced to the treatment of acute bacterial sinusitis, as 
adjuncts to systemic antibiotics. Interestingly, the infectious edema of acute sinusitis 
requires higher doses of steroids than those administered in allergic rhinitis(Moller et al., 
2010). In CRS, local steroids were at first prescribed cautiously, and only in case of 
exacerbations, which resemble the pathophysiology of acute rhinosinusitis. It was the 
beneficial effect of steroids on nasal polyposis and hyperplastic sinusitis, that indicated their 
prolonged use in CRS. When steroids are administered orally, they have a clearly superior 
effect on nasal polyps (“medical polypectomy”), than any form of topical treatment(Palmer 
and Kennedy, 2003). Naturally, the advantage of steroid sprays is their capacity for long-
term use with minimal side-effects. Perhaps the effective way to get the most out of 
corticosteroid therapy, is a combination of “induction” systemic administration to reduce 
the severe edema, along with a “maintenance” schedule of intranasal spaying, to control the 
continuous, low-grade inflammation of CRS(Wahl and Otsuji, 2003). 
Local steroids are administered in several forms, in order to achieve greater efficacy. 
Intranasal placement of fluticasone drops has demonstrated a distinct benefit in patients 
with hyperplastic CRS, precluding the need for endoscopic surgery in half of the cases. The 
authors suggest that nasal drops are more successful than sprays, as they reach easier the 
middle meatus(Aukema et al., 2005). A modification of drops administration involves direct 
instillation in the office, utilizing a soft catheter, under endoscopic vision. This method 
accomplishes focused application in difficult-to-approach regions, such as the frontal 
recess(Palmer and Kennedy, 2003). A more invasive technique, combining the efficacy of 
systemic treatment with the low side-effect pharmacological profile of local drops, utilizes 
injection of steroids into the polyp mass. Although this procedure has been performed 
enthusiastically in the 1950s, reports of visual loss emphasized the need for 
cautiousness(Mabry, 1981). Embolization or spasm of the central retinal artery, have been 
hypothesized as the mechanism of blindness. Placing the injection into the center of the 
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polyp lessens the risk of intra-arterial administration. Possibly, intra-polyp steroid injections 
do not have a role in the routine treatment of common CRS, but their efficacy could be 
useful in recalcitrant cases, not responding to oral or instilled corticosteroids(Antunes and 
Becker, 2010). 
The chronic topical therapy with steroids has raised concerns of absorption into the 
circulation, and their well-known systemic effects: growth inhibition due to hypothalamic 
suppression, loss of bone density, hypertension, diabetes, and psychosis(Demoly, 2008). 
From each sprayed dose, 30% of the medication stays within the sinonasal cavities, and 
undergoes metabolism on the nasal mucosa, whereas the remaining 70% follows the oral 
route and is subject to hepatic metabolism. Altogether, the absorption into the circulation 
depends largely on the steroid compound, and ranges from 49%(flunisolide) to less than 
0.1%(mometasone). A multitude of clinical studies has investigated the safety profile of 
intranasal steroids and no significant systemic side-effect was reported, either in adult or 
pediatric patients. Specifically for the latter, one-year duration of administration did not 
impede growth(Schenkel et al., 2000). Local adverse effects (dry rhinitis, epistaxis), 
sometimes causing considerable discomfort, have been documented, though(Giger et al., 
2003). Interestingly, even in the case of intranasal injection, there is no clinical or biochemical 
evidence of adrenal suppression, although raised plasma concentration of the steroid has 
been noted(Mabry, 1981). 
5.3 Antimicrobials 
Unquestionably, microorganisms have a fundamental role in the pathogenesis of CRS, either 
by maintaining prolonged infectious processes, or by generating toxic allergic reactions. 
Antibiotics have been persistently used for acute and chronic rhinosinusitis, in oral or 
intravenous form. The rationale for topical administration derives from the concept of 
biofilm, which is clearly an “epi-mucosal” phenomenon(Lim et al., 2008). Among the 
various advantages that the microenvironment of biofilms provides to microorganisms is its 
poor penetration by systemically administrated antimicrobial agents(Stewart and Costerton, 
2001). Moreover, the bacterial species found in biofilms, are no different from those 
commonly identified with conventional cultures in CRS (Al-Mutairi and Kilty, 2011). 
Interestingly, the minimal antibiotic concentration for the eradication of microorganisms 
residing in biofilms, can be as high as 1000 times their Minimal Inhibition Concentration 
(MIC) in the cultures from the same bacteria(Ceri et al., 1999). Therefore, chronic sinus 
infections refractory to culture-directed oral antibiotics was considered an indication for an 
alternative approach, which could overcome resistance by delivering high concentrations of 
medications in direct contact with the colonized epithelial coating. 
The choice of antibiotic should be based on endoscopically-guided culturing of sinus 
secretions, keeping in mind the multi-pathogen etiology of CRS. When it comes to selection 
among drugs to which microbes demonstrate equal sensitivity, antibiotics that kill bacteria 
once they reach a critical concentration (concentration-dependent), like quinolones or 
aminoglycosides, may exert a more potent bactericidal effect, in comparison with time-
dependent antibacterial medications. The latter, although effective in lower levels, require 
prolonged action at the target site. As already mentioned, the constant beating of the cilia 
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propels the mucosal coating out of the cavities in less than twenty minutes. Thus, antibiotics 
such as penicillins, cephalosporins, or macrolides, which are first-choice systemic treatment 
options for sinusitis, cannot be considered ideal for topical therapy, due to their rapid 
clearance(Palmer and Kennedy, 2003). An additional factor influencing the selection of 
topical agents is their differential metabolic processing locally and systemically. Drugs 
which are deactivated promptly in plasma, but remain intact in the sinus secretions, are both 
effective and safe. Mupirocin belongs to this class, and is currently the only FDA-approved 
medication for intranasal use(Uren et al., 2008). With regard to non-bacterial causes of CRS, 
fungi are considered a prominent etiologic factor, in up to 90% of cases in several 
studies(Ponikau et al., 1999). Therefore, antimycotic agents, like amphotericin B and 
itraconazole, are promising local agents, since their chronic systemic administration 
produces serious adverse effects. 
A few delivery methods have been tried for local antimicrobial therapy. Spraying of 
solutions with the use of atomizers, which is an efficient technique in the case of nasal 
steroids, has produced the poorest results. Small mucosal surface of initial application, along 
with the slow mucocliliary clearance which commonly accompanies CRS, possibly result in 
a limited area of drug deposition(Sykes et al., 1986). In contrast, sinus lavage with 
antibacterial solutions is more popular, and seems to be more effective as well. Frequent 
bottle irrigations with 300ml of ceftazidime, an antibiotic not available in oral form, are 
successful in eradicating Pseudomonas from patients with recalcitrant sinusitis(Leonard and 
Bolger, 1999). However, their efficacy may not be dependent solely on the proper delivery of 
the antibiotic, but also on the effects of the lavage itself, that is, the mechanical cleansing, 
dilution of mucus, and decrease of mucosal edema(Lim et al., 2008). A more advanced 
irrigation technique, employing endoscopic catheterization of the middle meatus, has 
achieved the resolution of CRS in the morbid context of cystic fibrosis. Yet, this modification 
of sinus rinsing requires frequent office visits, and interferes with patient compliance(Moss 
and King, 1995). Nebulization of antibiotics has emerged as both an effective and convenient 
delivery method. When the size of aerosolized particles is optimized to less than 5μm, this 
form of topical antimicrobial therapy is superior even to IV mode of administration. Similar 
to the case of antibiotic irrigations, an additional, non anti-infectious, beneficial mechanism 
of the aerosolized stream was postulated. Possibly, nebulization into the sinonasal cavities 
promotes anti-inflammatory and anti-edematous effects(Lim et al., 2008). 
The findings from studies investigating the efficacy of topical antimicrobial therapy, are 
quite encouraging. Up to 88% of patients experience significant improvement, good quality 
of life, and few local side effects (rhinitis), after four weeks of treatment(Vaughan and 
Carvalho, 2002). This symptomatic relief is concurrent with reversal of the endoscopic 
findings. Refractory infections by resistant strains of Staphylococcus aureus in particular, 
respond dramatically to irrigations with mupirocin solution(Uren et al., 2008).  On the other 
hand, topical application of antifungal agents did not produce a distinct therapeutic result in 
the management of CRS(Weschta et al., 2004). This finding is not in agreement with the 
hypothesis that fungal infection accounts for the majority of chronic sinusitis. Since fungi are 
ubiquitous in the environment and the sinus cavities, they seem impossible to be eradicated 
simply by local administration of antimycotic drugs. In the case of CRS induced by fungi, 
the pathogenesis entails an immune host reaction against fungal antigens, and as a result, 
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inflammatory modifiers might be more appropriate than any anti-infectious remedy(Lim et 
al., 2008). 
5.4 Mucoactive agents 
As stated previously, biofilms may alter significantly the pathophysiology of CRS and 
protect the pathogens from systemic or local treatments, thus perpetuating the infection. 
Not only that, but it is suggested that this bioorganic coating acts as a reservoir of bacteria, 
and releases microorganisms in the conventional “planktonik” form, into the sinus 
cavity(Al-Mutairi and Kilty, 2011). Obviously, novel approaches to refractory sinusitis cases, 
focus on the elimination of this enigmatic entity. Being a distinct structure, analogous to a 
foreign body, biofilm is an ideal target for topical therapy, as the regional vasculature might 
not deliver sufficient amounts of systemic medications to the interface between the 
epithelium and the colonized structure. 
Surfactants are ampthipathic compounds, that is, they possess both hydrophilic and 
lipophilic properties. Consequently, they are soluble both to water and organic substances. 
The well-known pulmonary surfactant decreases the adhesiveness of sputum to the lung 
respiratory epithelium, and facilitates the removal of mucus from the lung parenchyma. It is 
hypothesized that in a similar fashion, intranasally administered surfactants interfere with 
the adherence of the biofilm layer to the underlying sinus epithelium(Suh et al., 2010). This 
would result in biofilm peeling off the sinus walls, and the transition of recalcitrant CRS to a 
less complicated form, amenable to treatment. This scenario has been clinically tested in 
patients irrigating with baby shampoo, an inexpensive, nontoxic mixture of various 
surfactants. Almost half of the patients reported a marked improvement in their “mucus-
related” symptoms, i.e. thick nasal discharge and post-nasal drip(Chiu et al., 2008). 
Secondary effects of surfactants have also been postulated, such as destabilization of 
bacterial membranes with leaking of electrolytes. 
A promising local agent, due to its safety profile and low cost, is honey. In vitro testing 
documented eradication of Staphylococcus aureus and Pseudomonas aeruginosa in biofilm 
colonies, after treatment with several types of honey. Notably, honey was effective even 
against Methicillin Resistant Staphylococcus Aureus (MRSA), which is considered a plague 
of our time(Alandejani et al., 2009). The exact antimicrobial and mucoactive properties of 
honey are yet to be discovered. 
5.5 Decongestants 
Intranasal decongestants are the most frequently local agents used by sinusitis patients 
(16%) in the United States, more often even than local steroids. Perhaps the high prevalence 
of use can be explained by their availability over the counter, as well as the rapid, almost 
immediate, relief they provide from nasal congestion. Physicians usually prescribe a short-
term course of decongestant sprays only in cases of severe, acute exacerbations of 
CRS(Sharp et al., 2007). Local decongestants are sympathomimetic agonists, which stimulate 
alpha-adrenergic receptors on the smooth-muscle fibers of the vessels beneath the nasal 
respiratory epithelium. As a result, brisk, potent vasoconstriction ensues. Interestingly, local 
sympathomimetics and steroids produce decongestion via different mechanisms, so that an 
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additive effect could be accomplished by concurrent use of the two medications(Yoo et al., 
1997). Although vasoactive decongestants reverse fast and effectively the mucosal edema, 
their local complications (rebound congestion, dry rhinitis, epistaxis) preclude their chronic 
use(Eccles et al., 2008). 
5.6 Antihistamines 
Antihistamines do not treat rhinosinusitis per se, but they alleviate the mucosal 
inflammation of allergic rhinitis. Although allergic rhinitis reasonably seems a predisposing 
factor for CRS, a direct etiologic relationship has not been demonstrated. Nonetheless, the 
incidence of CRS is higher in patients with allergic rhinitis or atopy. Furthermore, chronic 
sinusitis in the setting of allergic rhinitis is more resistant either to medical or surgical 
treatment, than the CRS variant of the non-allergic population(Krouse, 2000). Therefore, 
antihistamines could be incorporated into the management plan of selected CRS cases. 
Systemic antihistamines have been traditionally used in allergic rhinitis, with certain central 
nervous side-effects, such as sedation, poor attention, and impaired school or work 
performance. 
Aiming to achieve maximum therapeutic action, as well as a lower rate of adverse effects, 
intranasally sprayed antihistamines are now included in the treatment armamentarium. 
Topical agents (azelastine, olopatadine) have shown indeed superior efficacy and safer 
profile than oral antihistamines. Moreover, they have the fastest onset of action (15 minutes 
for azelastine), among all the drugs administered for rhinitis, whether systemically or 
topically(Horak and Zieglmayer, 2009). Olopatadine, is well tolerated in children without 
causing somnolence, or compromising school performance(Berger et al., 2009). Interestingly, 
azelastine, besides blocking H1-receptors, exerts a few anti-inflammatory effects, e.g. mast-
cell stabilization, inhibition of Tumor Necrosis Factor-alpha, and reduction of pro-
inflammatory cytokines. Thus, it is effective in both allergic and non-allergic rhinitis(Horak 
and Zieglmayer, 2009). 
6. Our experience in topical CRS therapy 
6.1 The rhinotopic protocol: Why we do it 
As already mentioned, chronic rhinosinusitis is persistent and symptomatic even after 
optimal medical or surgical management, in 5-25% of cases. In spite of widely open sinus 
cavities that are ventilated and drain readily to the nasal cavity, the mucosa is still inflamed 
and edematous, often with gross polyposis. We suspect that this variant of CRS is a medical 
disease, and the element of surgical obstruction is not the key pathogenetic factor. The sinus 
mucosa itself may be inherently predisposed to sustained inflammation, and in that case, it 
should be the target of pharmacological interventions. Even when these patients receive 
maximal standard medical treatment, sinus inflammation responds poorly or temporarily, 
and relapses are very common.  
Consequently, patients undergo multiple surgical procedures, essentially for polyp 
debulking only, receive high doses of systemic steroids or potent antibiotics, and follow 
long courses of immunotherapy or desensitization therapy to address the allergic 
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component of rhinosinusitis. Chronic or recurrent severe symptoms, impose a considerable 
cost burden due to multiple ineffective treatment attempts, but also impair dreadfully the 
quality of life. The frustration that patients naturally experience, introduces the “psycho-
sinus” component to the natural history of refractory CRS. Typically, patients are fatigued, 
depressed and express their hopelessness. They confront the rhinologist with their feelings 
of disappointment and questions about new promising therapies, whereas they soon 
become non-compliant with the physician’s instructions. The emotional distress of CRS 
sufferers is more debilitating than that of more severe, life-threatening chronic illnesses, 
such as congestive heart failure and chronic obstructive pulmonary disease(Gliklich and 
Metson, 1995).  
The rhinotopic protocol is a comprehensive form of topical therapy for CRS unresponsive to 
standard regimens. It focuses on sinus membrane therapy, and aims to provide long-term 
alleviation of symptoms, with minimal discomfort and adverse effects.  
6.2 The rhinotopic protocol: How we do it 
The rhinotopic protocol originated in our rhinology practice, in a teaching community 




1. Previous endoscopic sinus surgery. 
2. Recurrent or chronic sinusitis symptoms. 
3. Endoscopic and radiologic evidence of sinus mucosal thickening or polyps.  
4. Endoscopic and radiologic evidence of patent sinus ostia. 
5. Trial of at least 2 courses of oral antimicrobial treatment without significant 
improvement. 
6. Prolonged use of standard local treatments (saline irrigations, intranasal steroid sprays, 
intranasal decongestants)     
Exclusion criteria: 
1. Minor (<18 years of age). 
2. Patient above 80 years of age. 
3. Pregnant and breastfeeding women. 
4. Allergy to specific antibiotics. 
5. Patient currently taking oral corticosteroids. 
6. Patient currently taking oral antibiotics. 
6.2.2 Protocol design 
The rhinotopic protocol is a strictly local form of CRS therapy, and does not involve 
administration of any systemic medications at any point. Two weeks prior to the beginning 
of treatment, a swab aerobic & anaerobic culture is taken endoscopically from the middle 
meatus to determine the dominant microorganism(s). Under local anesthesia, a piece of 
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diseased mucosa is excised for histopathological assessment, as well as identification and 
quantification of the supra-epithelial biofilm layer.  
The patients follow a 6-week regimen at home, consisting of saline irrigations twice a day, 
followed by intranasal aerosolization (Fig. 2) of mometasone and an antibiotic chosen based 
on the pre-treatment naso-endoscopic guided swab culture. These drugs are FDA approved 
and already being used clinically both in pill form and liquid (injectable) formulations for 
the treatment of infections. 
Mometasone is among the most potent intranasally used steroids, in terms of its affinity 
with the glucocorticoid receptor(Derendorf and Meltzer, 2008). The culture-directed 
antibiotic is selected among several concentration-dependent agents, with minimal systemic 
absorption: levofloxacin, tobramycin, mupirocin, and vancomycin. The steroid/antibiotic 
aerosolized mixture is self-administered using a vibrating mesh nebulizer, which creates an 
aerosol mist by a rapidly vibrating mesh with hundreds of 4 to 8 μm holes, and allows a fast 
and uniform delivery of small aerosolized medication particles to the sinus walls. 
In addition, endoscopic nasal toilet, with careful removal of biofilm and crusts from the 
sinuses, will be performed weekly by the treating rhinologist after the application of 
numbing spray in the nasal cavity. Following nasal toilet, topical mometasone and culture-
directed antibiotic preparations are instilled inside the sinus cavities using a curved suction 
tip (Fig. 2). The drugs are introduced into the sinuses in a gel form (Fig. 3), which is 
prepared by a pharmacy, specifically for the needs of the rhinotopic protocol. Three mL of 
gel are instilled in each side, and distributed evenly in the maxillary sinus cavity, along the 
opened sphenoid and ethmoid cells, and towards the frontal recess. This drug-containing 
hydrophilic gel contains the non-ionic ether hydroxyethyl cellulose, which is a 
mucoadhesive agent. Upon its placement into the paranasal sinuses, it forms a 
mucoadherent film, resistant to erosion, which remains in contact with the respiratory 
epithelium. The prolonged attachment of the polymer matrix to the diseased mucosa, 
facilitates effective drug release onto the pharmacological target, and negates the 
mucociliary clearance of therapeutic agents(Ugwoke et al., 2005). Patients are advised to 




Fig. 2. The NasoNeb™ nebulizer (Left) is used for drug aerosolization in the rhinotopic 
protocol, and the hydroxyethyl cellulose gel (Right) is instilled through a curved suction tip. 
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Fig. 3. The steroid & antibiotic releasing gel is introduced into the left maxillary and ethmoid 
cavities with a curved suction. 
The duration of the protocol is six weeks, and one month later, the swab culture and the 
biopsy of the mucosa are repeated, to document the effect of treatment on the bacteriology, 
pathology, and biofilm formation.  
On each patient encounter after treatment beginning (weekly debridement visits, one and 
two months post treatment), the clinical response to the protocol is monitored (Fig. 4). The 
evaluation outcome is quantified using the Lund-Kennedy (LK) symptoms score and the 
endoscopic appearance score(Lund and Kennedy, 1997). 
 
Fig. 4. Graphic of the protocol time-plan (numbers represent days). 
6.2.3 Risks 
The most serious possible side effects of the topical treatment protocol may include: 
 Early and/or late recurrence of sinus symptoms. 
 Allergic reaction to the antibiotic. If the patient has ever had any unusual or allergic 
reaction to any of the medications that are to be instilled, then these will be avoided, 
and another medication will be chosen.   
 Subjects will be inconvenienced only by the need to undergo pre- and post-treatment 
biopsies of sinus mucosa. Bleeding, pain and infection may occur as a result of biopsies.  
 Since there is minimal systemic absorption, we do not expect any immunosuppressive 
effect of the corticosteroids or any adrenal suppression effect. As mentioned previously, 
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6.2.4 Patient monitoring 
The response to treatment is assessed by pre- and post-therapeutic evaluation of four 
clinicopathological parameters: 
 LK symptom (Table 1) and endoscopic scores (Table 2).  
 
Symptom Score 
Nasal blockage or congestion 0-10 
Headache 0-10 
Facial Pain 0-10 
Hyposmia 0-10 
Nasal discharge or post-nasal drip 0-10 
Sneezing 0-10 
Total Symptom Score 0-60 
Table 1. Lund-Kennedy symptom scale: The patient is interviewed with regard to the 
severity of his symptoms over the past week, and provides a score of 0 (absent symptom) to 
10 (maximum possible symptom).  
Endoscopic feature Score 
 R L 
Edema 0-2 0-2 
Polyps 0-2 0-2 
Discharge 0-2 0-2 
Crusting 0-2 0-2 
Adhesions 0-2 0-2 
Total Endoscopic Score 0-20 
Table 2. Lund-Kennedy endoscopic appearance scale: The rhinologist assesses five 
endoscopic parameters on each side, providing a score of 0, 1, or 2, as follows: Edema, 
adhesions, and discharge: 0-absent, 1-mild, 2-severe. Polyps: 0-absent, 1-polyps only in 
middle meatus, 2-polyps extending beyond middle meatus. Discharge: 0-clear, 1-thin 
secretions, 2-thick, purulent secretions. 
 Swab culture from the middle meatus. 
 Histopathological diagnosis and grading of the mucosal inflammation. In detail, 
characteristics of chronic inflammation (epithelial necrosis, sub-mucosal edema, 
polypoid degeneration, lymphocyte infiltration) are identified on Hematoxylin & Eosin 
tissue sections. 
 Biofilm quantification. A piece of the mucosa specimen is subjected to a colony forming 
units - assay, which provides an estimate of the biofilm’s bacterial burden. 
6.2.5 Rhinotopic study 
In order to assess the efficacy of the rhinotopic protocol, we conducted a prospective study 
with the participation of 20 patients. All subjects suffered from refractory CRS, and fulfilled 
the inclusion criteria for receiving the rhinotopic therapy. This study tested the hypothesis 
that direct intra-sinus administration of antibiotics and steroids in a gel & aerosol media, in 
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addition to frequent sinus cleansing, restores the health of the mucosa, prevents adhesion 
formation, reduces polyp recurrence, and eradicates sinus pathogens that are otherwise 
resistant to other types of treatment. We did not use a control group, because every 
candidate for rhinotopic therapy had been unsuccessfully treated in the past with a standard 
regimen of oral antibiotics, so that all controls by definition represent treatment failures. 
The study population included 12 women (60%) and 8 men (40%), with age range from 13 to 
76 years (mean age: 48 years). Four patients (20%) were tested positive in allergy workup 
(allergen-specific IgE measurement) upon enrolment, and received immunotherapy. Two 
patients (10%) presented with the Samter’s triad of symptoms, and leukotriene inhibitors 
were prescribed. The most commonly cultured aerobic bacteria were Staphylococcus aureus 
(8 cases, 40%), and Pseudomonas aeruginosa (6 patients, 30%). Anaerobe growth was not 
documented. The culture-directed antibiotics that were used in the study included 
tobramycin in 14 cases (70%), vancomycin and levofloxacin.  
Outcome measures of the sudy were the differences between pre- and post-treatment LK 
symptom/endoscopic scores, swab culture results, histological gravity of chronic 
inflammation, as well as the bacterial density of the supra-epithelial biofilm. There was a 
statistically significant improvement between the mean pre- and post-treatment LK 
symptom and endoscopic appearance scores (student’s t-test, P<0.001). All six LK symptoms 
were individually improved as well. The post-treatment culture results showed no growth 
in 65% of the cases, normal respiratory flora in 25%, and infection by the original pathogenic 
organism in 10%. Comparison of histopathological findings in the pre- and post-treatment 
specimens, revealed a substantial reversal of almost all indices of chronic inflammation (Fig. 
5). With regard to the bacterial density of biofilm, the mean number of CFUs/ml has 
decreased by 98.7%, one month after the completion of the rhinotopic protocol. This sharp 
drop clearly indicates the elimination of viable microorganisms within the biofilm matrix.  
 
Fig. 5. Histopathological microphotographs of sinus mucosa in CRS. Left: Before the 
rhinotopic protocol, epithelial attenuation, disruption of epithelia layer, and marked 
eosinophilic inflammation are evident. Right: Post-treatment, epithelial integrity increases 
and inflammation resolves.  
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None of the patients reported any systemic or local adverse reactions. Careful endoscopy 
during the follow-up visits, did not reveal severe irritation, crusting, or signs of recent 
epistaxis.  
6.2.6 The rhinotopic protocol: How it works 
Refractory chronic sinusitis is a multifactorial disease, and its chronicity relies on constant 
debris accumulation, unremitting inflammation, and insidious infection. The optimal 
management needs to be multifactorial as well, and address all three components 
concurrently. The rhinotopic protocol is a comprehensive, strictly topical, approach to this 
difficult-to-treat entity. It is not applied routinely to any CRS case, but it is rather indicated 
for selected patients, who had previously received high-quality surgical and medical 
treatment, but continue to experience prolonged symptoms of moderate to severe intensity. 
Mechanical cleansing by means of frequent high-pressure saline irrigations and weekly 
office debridements, although simple, ensures the efficacy of the pharmacological 
interventions. Crusts, mucopurulent secretions, and exudates, are toxic to the underlying 
epithelium, and perpetuate the inflammation. Meticulous removal of debris is the sine qua 
non of every topical therapy, in the same way it is essential for the normal healing process 
post-sinus surgery(Palmer and Kennedy, 2003). 
The anti-inflammatory effect of the treatment is achieved by the sustained action of 
mometasone, one of the most potent commercially available steroids. The steroid is applied 
locally via a combination of two advanced delivery techniques, i.e., nebulization of small 
aerosolized particles, and endoscopically-guided instillation of a mucoadhesive gel. 
Remarkable edema reduction, and down-regulation of the eosinophilic infiltration, are 
among the proven consequences of systemic steroid use. Even though, this clinical 
improvement may not be very long-lasting. According to our data, resolution of 
inflammation-related symptoms, such as congestion, nasal discharge, and facial tenderness, 
is still documented one month after the topical protocol’s completion. 
Antimicrobial agents are administered simultaneously with the steroids, via the same two 
delivery methods. The role of infection in chronic sinusitis is unclear, and it is common 
belief that CRS exacerbations are pathophysiologically analogous to acute sinusitis, and 
should be treated as such.  Typically, culture-directed systemic antibiotics may temporarily 
suppress the infection, but recurrence caused by the same pathogen is frequently noted(Lim 
et al., 2008). The sustained, highly concentrated application of antimicrobial agents directly 
onto the diseased membrane, according to the rhinotopic protocol, aims to eradicate the 
etiologic microorganism from the sinus mucosa. It is suggested that a key factor for the 
successful elimination of infection is overcoming the resistance of bacteria within the biofilm 
shelter. The antibiotic-releasing mucoadherent gel is specifically attached to this surface-
organized community, and places a dense concentration of bactericidal agents at the 
infection site. Our findings show an impressive decline in the population of viable bacteria 
residing in biofilms, as assayed by Colony Forming Units cultures, following the rhinotopic 
therapy. This suggests that one of the mechanisms responsible for the protocol’s efficacy is 
the disruption of biofilms. A contributing factor to the biofilm extirpation, may be the high-
pressure hydrotherapy performed by the patient alternately with the antibiotic 
administration. Saline irrigations possibly wash out panktonik bacteria before they become 
fixed to sinus walls and recolonize the organic matrix(Suh et al., 2010). 
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Chronic rhinosinusitis is evidently a unique disease process, and far more complex than 
what we commonly describe as an “infection”. CRS refractory to standard treatment is not 
an exception to the rule, but rather an increasingly occurring phenomenon. In such a chronic 
illness, the side-effects of systemic medications underlie the necessity of topical therapy. The 
latter, as this chapter has showed, is not merely restricted to placement of a drug locally, but 
has been developed with the help of technology into a dynamic approach, tailored to the 
disease’s pathophysiology. Advances in endoscopy and particularly in sinus surgery, have 
made the paranasal cavities accessible to application of a variety of pharmacological agents.  
Our proposal is an integrated topical protocol, for the restoration of the sinus mucosa 
homeostasis. Preliminary results are promising, and the ultimate goal of this approach is to 
establish a long-term effect after treatment completion, rather than transient symptom relief. 
Longer follow-up of patients, and modifications of the protocol guided by ongoing findings, 
would be the next step. 
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